Human Genome Sciences is focused on building an international organization and is committed to making BENLYSTA® (belimumab) available worldwide.

HGS Europe’s headquarters are located in Lausanne, Switzerland, and local organizations are operational in Germany, France and Spain. HGS Europe is responsible for European sales, marketing and medical affairs across the HGS product portfolio.

In July 2011, the European Commission granted marketing authorization for BENLYSTA as an add-on therapy in adult patients with active autoantibody-positive systemic lupus erythematosus, with a high degree of disease activity (e.g. positive anti-dsDNA and low complement), despite standard therapy. HGS and GlaxoSmithKline (GSK) are developing BENLYSTA under a co-development and co-commercialization agreement entered into in 2006.

HGS Europe has a commercialization team in place to work alongside GSK to bring BENLYSTA to patients with systemic lupus. Outside of countries where we have established local organizations, GSK will lead implementation.

For more information, please contact:

European Headquarters/Switzerland office: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Germany: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
France: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Spain: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it